Informations générales (source: ClinicalTrials.gov)

NCT01566019 Statut inconnu
Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment (MOSCATO 02)
Interventional
N/A
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
octobre 2011
octobre 2020
29 juin 2024
The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival compared to the previous treatment line. The secondary objectives are to investigate clinical practical feasibility of such technics, to potentially improve the overall survival of patients and to describe molecular portrait of Phase 1 candidates.
 Voir le détail

Etablissements

Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CLCC INSTITUT GUSTAVE ROUSSY Jean-Charles SORIA, MD, PhD En recrutement IDF Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- Solid tumors ; Stade IV ; Local relapse or metastatic ; Uncurable

- Age > 6 months

- PS 0/1 or Lansky play scale >= 70%

- Minimum one treatment line, no limit in the prior number of treatment line

- Evaluable or measurable disease


- Life expectancy < 3 months

- Carcinomatous meningitis

- Symptomatic or progressive radiologic brain metastasis for non-CNS tumors

- Polynuclear neutrophil < 1 x 10^9/L

- Platelets < 100 x 10^9/L

- Hemoglobin < 90 g/L

- ALT/AST > 2.5 N

- bilirubin > 1.5 N

- Creatinine >1.5 N

- Calcemia > ULN

- Phosphate > ULN

- Coagulation anomaly non-indicated for biopsy